Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response.
Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response.
复制标题
DOI：
10.1038/bjc.2012.345
复制
发表时间：
2012-08-21
影响因子：
8.8
通讯作者：
Bristow, R. G.
中科院分区：
文献类型：
--
作者：
Thoms, J. W.;Dal Pra, A.;Anborgh, P. H.;Christensen, E.;Fleshner, N.;Menard, C.;Chadwick, K.;Milosevic, M.;Catton, C.;Pintilie, M.;Chambers, A. F.;Bristow, R. G.
高血浆骨桥蛋白（OPN）与肿瘤缺氧、转移和不良预后有关。本研究旨在评估血浆骨桥蛋白是否是前列腺癌（PCa）预后组内进展增加的生物标志物，以及它是否反映了对局部和全身治疗的治疗反应。基线 OPN 在患有局限性 (n = 199)、局部复发 (n = 9) 和去势抵抗性转移性前列腺癌 (CRPC-MET；n = 37) 的男性中确定。生成受试者工作曲线 (ROC) 来描述 OPN 区分局部风险组或局部与转移性疾病的准确性。我们还测量了治疗前和治疗后、根治性前列腺切除术、外照射放射治疗 (EBRT)、雄激素剥夺 (AD) 或基于紫杉烷的化疗后的 OPN。与局部非转移组（平均 72；12–438ngml−1）相比，CRPC-MET 患者的基线值升高（平均 219；56–513ngml−1；P<0.0001）。当 OPN 添加到前列腺特异性抗原 (PSA) 中时，区分局部疾病和转移性疾病的 ROC 下面积得到改善 (0.943–0.969)。骨桥蛋白既不能区分高危前列腺癌和其他局部前列腺癌，也不能与基线时的血清 PSA 相关。根治性前列腺切除术后低危患者（P=0.005）和化疗后 CRPC-MET 患者（P=0.027）骨桥蛋白水平降低，但 EBRT 或 AD 后骨桥蛋白水平没有降低。血浆 OPN 与 PSA 一样可以预测 CRPC-MET 患者化疗后的治疗反应。我们的数据不支持使用血浆 OPN 作为局部 PCa 内肿瘤负荷增加的生物标志物。
High plasma osteopontin (OPN) has been linked to tumour hypoxia, metastasis, and poor prognosis. This study aims to assess whether plasma osteopontin was a biomarker of increasing progression within prostate cancer (PCa) prognostic groups and whether it reflected treatment response to local and systemic therapies. Baseline OPN was determined in men with localised (n=199), locally recurrent (n=9) and castrate-resistant, metastatic PCa (CRPC-MET; n=37). Receiver-operating curves (ROC) were generated to describe the accuracy of OPN for distinguishing between localised risk groups or localised vs metastatic disease. We also measured OPN pre- and posttreatment, following radical prostatectomy, external beam radiotherapy (EBRT), androgen deprivation (AD) or taxane-based chemotherapy. The CRPC-MET patients had increased baseline values (mean 219; 56–513 ng ml−1; P<0.0001) compared with the localised, non-metastatic group (mean 72; 12–438 ng ml−1). The area under the ROC to differentiate localised vs metastatic disease was improved when OPN was added to prostate-specific antigen (PSA) (0.943–0.969). Osteopontin neither distinguished high-risk PCa from other localised PCa nor correlated with serum PSA at baseline. Osteopontin levels reduced in low-risk patients after radical prostatectomy (P=0.005) and in CRPC-MET patients after chemotherapy (P=0.027), but not after EBRT or AD. Plasma OPN is as good as PSA at predicting treatment response in CRPC-MET patients after chemotherapy. Our data do not support the use of plasma OPN as a biomarker of increasing tumour burden within localised PCa.
登录
查看更多内容
影响因子：
11.5
作者：
Bramwell, Vivien H. C.;Doig, Gordon S.;Chambers, Ann F.
通讯作者：
Chambers, Ann F.
影响因子：
8.8
作者：
Rittling, SR;Chambers, AF
通讯作者：
Chambers, AF
影响因子：
11.5
作者：
Hui, Edwin P.;Sung, Fion L.;Chan, Anthony T. C.
通讯作者：
Chan, Anthony T. C.
影响因子：
11.5
作者：
Castellano, Giancarlo;Malaponte, Grazia;Libra, Massimo
通讯作者：
Libra, Massimo
影响因子：
51.1
作者：
Vergis, Roy;Corbishley, Catherine M.;Parker, Chris
通讯作者：
Parker, Chris